Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07217678 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use

Name: Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use — clinical trial record (NCT07217678)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 4

SponsorUniversity of Miami

Started2026-02-09

View on ClinicalTrials.gov ↗

Amendment history

2026-03-03

Study Status v2

Start dateestimated 2026-03→confirmed 2026-02-09

2026-02-06

Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1

Trial statusNot Yet Recruiting→Recruiting

Start date2026-01-31→2026-03

Study sitesdetails revised at 1 of 1 site

2025-10-14

Original filing

University of Miami

241 trials monitored

See 29 trials at risk

The objective of this study is to evaluate whether reduction in topical medication with the injection of a sustained release capsule (Durysta) leads to a reduction in ocular surface inflammation, indicated by levels of caspase-1, an inflammatory biomarker.

Trial Details

NCT Number	NCT07217678
Lead Sponsor	University of Miami Collaborators: AbbVie
Conditions	Glaucoma, Open-Angle Glaucoma, Ocular Hypertension, Glaucoma Suspect
Enrollment	20 participants
Start Date	2026-02-09
Primary Completion	2028-01-31 (estimated)
Study Completion	2028-01-31 (estimated)
Updated on ClinicalTrials.gov	2026-03-05